Önder Alpdoğan

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 645 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Ocular surface epithelia contain ABCG2-dependent side population cells exhibiting features associated with stem cells

Murat T. Budak, Önder Alpdoğan, Mingyuan Zhou et al. · Journal of Cell Science · 2005 · 234 citations · Full text

Life Sciences, Cell Biology, Ophthalmology +10

Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration

Önder Alpdoğan, Vanessa M. Hubbard, Odette M. Smith et al. · Blood · 2005 · 217 citations · Full text

Life Sciences, Cell Biology, Developmental Biology +11

Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease

Önder Alpdoğan, Cornelius Schmaltz, Stephanie J. Muriglan et al. · Blood · 2001 · 210 citations

Life Sciences, Hematology, Immunology +16